SCHEMBL8404474

SCHEMBL8404474

Cc1nc[nH]c(=O)c1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6765002 0.76
SCHEMBL21273026 0.76
SCHEMBL19493860 0.76
SCHEMBL17773604 0.76
SCHEMBL503673 0.76
SCHEMBL12138872 0.76
SCHEMBL20180773 0.75 PDPK1 (0.43)
SCHEMBL9902092 0.73 CYP1A2 (0.42)
SCHEMBL14144467 0.73 PDPK1 (0.43)
SCHEMBL13693761 0.73 HTT (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025011617-A1 FUSED HETEROAROMATIC RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF 杭州圣域生物医药科技有限公司 2025-01-16 WO disclosed
CN-119306741-A Fused-ring heteroaromatic ring compound, intermediate, preparation method and application 杭州圣域生物医药科技有限公司 2025-01-14 CN disclosed
CN-113226323-B Ma Dexin derivative compounds, compositions and uses thereof for the treatment of cancer 法国古士塔柏罗斯学院 2024-12-31 CN disclosed
WO-2024173343-A1 COMPOUNDS TARGETING HYDROXYSTEROID 17-BETA DEHYDROGENASE (HSD17B) AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-08-22 WO disclosed
CN-115003658-B Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency 森特萨制药(英国)有限公司 2024-07-23 CN disclosed
EP-4073043-B1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY CENTESSA PHARMACEUTICALS UK LTD (GB) 2024-04-03 EP disclosed
US-20230102488-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY OXFORD FINANCE LLC 2023-03-30 US disclosed
WO-2022263829-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY Z Factor Limited (GB) 2022-12-22 WO disclosed
EP-4073043-A1 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY Z Factor Limited (GB) 2022-10-19 EP disclosed
CN-115003658-A Compounds and their use in the treatment of alpha 1 Use against trypsin deficiency Z因子有限公司 2022-09-02 CN disclosed
WO-2010140685-A1 HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER 日産化学工業株式会社 (JP) 2010-12-09 WO disclosed
US-20100266556-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2010-10-21 US disclosed
US-20100266556-A1 METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2010-10-21 US disclosed
US-20100130512-A1 FUSED-RING HETEROCYCLE OPIOIDS RENSSELAER POLYTECHNIC INSTITUTE (US) 2010-05-27 US disclosed
US-20100130512-A1 FUSED-RING HETEROCYCLE OPIOIDS RENSSELAER POLYTECHNIC INSTITUTE (US) 2010-05-27 US disclosed
US-20100008866-A1 CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2010-01-14 US disclosed
US-20090069347-A1 2-phenoxy pyrimidinone analogues NEUROGEN CORPORATION (US) 2009-03-12 US disclosed
WO-2008144394-A2 FUSED-RING HETEROCYCLE OPIOIDS RENSSELAER POLYTECHNIC INSTITUTE (US) 2008-11-27 WO disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20070078152-A1 Piperidine derivatives AMGEN INC. 2007-04-05 US disclosed